Advicenne SA logo

ADVIC - Advicenne SA News Story

€7.08 0.1  1.1%

Last Trade - 11/08/20

Sector
Healthcare
Size
Small Cap
Market Cap £52.9m
Enterprise Value £39.0m
Revenue £1.49m
Position in Universe 558th / 852

BRIEF-Advicenne Receives Health Canada Clearance To Extend Its Pivotal Phase III Trial Of Adv7103 In Canada

Mon 15th October, 2018 5:28pm
Oct 15 (Reuters) - ADVICENNE SA  ADVIC.PA :
    * ADVICENNE RECEIVES HEALTH CANADA CLEARANCE TO EXTEND ITS PIVOTAL PHASE III TRIAL OF
ADV7103 IN
CANADA
    * RECEIVED A NO OBJECTION LETTER TO EXTEND ITS ARENA-2 PIVOTAL PHASE III TRIAL FOR TREATMENT
OF
DISTAL RENAL TUBULAR ACIDOSIS (DRTA) IN CANADA

Source text for Eikon:  ID:nBw3yTFFDa 
Further company coverage:  ADVIC.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.